Nghi Maokhamphiou
Medical · Sacramento, CANPI 1538201504
Payments from drug & device makers
Across 289 payments — averaging $22.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$985
- GSK$411
- Viiv Healthcare Company$360
- Boehringer Ingelheim$352
- Novartis$322
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,489100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 42 | $1,027 |
| Novo Nordisk | 52 | $985 |
| GSK | 12 | $411 |
| Viiv Healthcare Company | 16 | $360 |
| Boehringer Ingelheim | 16 | $352 |
| Novartis | 18 | $322 |
| Amgen | 6 | $286 |
| AbbVie | 9 | $270 |
| AstraZeneca | 9 | $257 |
| Pfizer | 14 | $234 |
| Johnson & Johnson | 8 | $175 |
| Sanofi Pasteur Inc. | 7 | $166 |
| BD | 7 | $146 |
| Merck | 7 | $145 |
| Gilead | 4 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $134 |
| Abbott | 7 | $129 |
| Alk-abello, Inc | 6 | $124 |
| Biohaven Pharmaceuticals, Inc. | 6 | $114 |
| Hologic Sales And Service, LLC | 4 | $95 |
| Scilex Pharmaceuticals Inc. | 4 | $69 |
| Dexcom, Inc. | 2 | $63 |
| Exact Sciences | 3 | $61 |
| Kowa Pharmaceuticals America, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Bayer | 2 | $38 |
| Edwards Lifesciences | 2 | $37 |
| Cranial Technologies, Inc | 3 | $37 |
| Phadia US Inc. | 2 | $34 |
| Cipher Pharmaceuticals US LLC | 1 | $32 |
| Mylan Specialty L.p. | 2 | $27 |
| Qiagen, LLC | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,489 in reported general payments places this provider in the 90th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 91 | $122,931 |
| TradjentaLinagliptin | 92 | $109,721 |
| JanuviaSitagliptin Phosphate | 91 | $99,538 |
| RybelsusSemaglutide | 46 | $65,303 |
| TrulicityDulaglutide | 46 | $53,592 |
| OzempicSemaglutide | 42 | $52,736 |
| EliquisApixaban | 50 | $46,171 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 100 | $39,815 |
| EntrestoSacubitril/Valsartan | 34 | $31,192 |
| VemlidyTenofovir Alafenamide | 16 | $21,906 |
| FarxigaDapagliflozin Propanediol | 20 | $14,272 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 321 | $10,962 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 139 | $9,193 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $9,148 |
| Arnuity ElliptaFluticasone Furoate | 31 | $7,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $352 | $232,652183 claims |
| Novo NordiskRybelsus, Ozempic | $985 | $118,03988 claims |
| MerckJanuvia, Janumet | $145 | $106,857103 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $1,027 | $58,79681 claims |
| PfizerEliquis | $234 | $46,17150 claims |
| NovartisEntresto | $322 | $31,19234 claims |
| GileadVemlidy | $143 | $21,90616 claims |
| AstraZenecaFarxiga, Brilinta | $257 | $20,89034 claims |
| GSKArnuity Ellipta | $411 | $7,95631 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $69 | $2,87044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 medical providers in California.
Other medical in Sacramento
- Kathryn CunninghamSacramento$91K
- Jacinda ChanSacramento$31K
- Joshua OppermanSacramento$26K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.